Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Case report

Complete staghorn calculus in polycystic kidney disease: infection is still the cause

Authors: Zhiguo Mao, Jing Xu, Chaoyang Ye, Dongping Chen, Changlin Mei

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Kidney stones in patients with autosomal dominant polycystic kidney disease are common, regarded as the consequence of the combination of anatomic abnormality and metabolic risk factors. However, complete staghorn calculus is rare in polycystic kidney disease and predicts a gloomy prognosis of kidney. For general population, recent data showed metabolic factors were the dominant causes for staghorn calculus, but for polycystic kidney disease patients, the cause for staghorn calculus remained elusive.

Case presentation

We report a case of complete staghorm calculus in a polycystic kidney disease patient induced by repeatedly urinary tract infections. This 37-year-old autosomal dominant polycystic kidney disease female with positive family history was admitted in this hospital for repeatedly upper urinary tract infection for 3 years. CT scan revealed the existence of a complete staghorn calculus in her right kidney, while there was no kidney stone 3 years before, and the urinary stone component analysis showed the composition of calculus was magnesium ammonium phosphate.

Conclusion

UTI is an important complication for polycystic kidney disease and will facilitate the formation of staghorn calculi. As staghorn calculi are associated with kidney fibrosis and high long-term renal deterioration rate, prompt control of urinary tract infection in polycystic kidney disease patient will be beneficial in preventing staghorn calculus formation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mufti UB, Nalagatla SK: Nephrolithiasis in autosomal dominant polycystic kidney disease. J Endourology Endourological Soc. 2010, 24 (10): 1557-1561. 10.1089/end.2010.0093.CrossRef Mufti UB, Nalagatla SK: Nephrolithiasis in autosomal dominant polycystic kidney disease. J Endourology Endourological Soc. 2010, 24 (10): 1557-1561. 10.1089/end.2010.0093.CrossRef
2.
go back to reference Nishiura JL, Neves RF, Eloi SR, Cintra SM, Ajzen SA, Heilberg IP: Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. CJASN. 2009, 4 (4): 838-844.CrossRefPubMedPubMedCentral Nishiura JL, Neves RF, Eloi SR, Cintra SM, Ajzen SA, Heilberg IP: Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. CJASN. 2009, 4 (4): 838-844.CrossRefPubMedPubMedCentral
3.
go back to reference Gambaro G, Fabris A, Puliatta D, Lupo A: Lithiasis in cystic kidney disease and malformations of the urinary tract. Urol Res. 2006, 34 (2): 102-107. 10.1007/s00240-005-0019-z.CrossRefPubMed Gambaro G, Fabris A, Puliatta D, Lupo A: Lithiasis in cystic kidney disease and malformations of the urinary tract. Urol Res. 2006, 34 (2): 102-107. 10.1007/s00240-005-0019-z.CrossRefPubMed
4.
go back to reference Torres VE, Wilson DM, Hattery RR, Segura JW: Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993, 22 (4): 513-519.CrossRefPubMed Torres VE, Wilson DM, Hattery RR, Segura JW: Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993, 22 (4): 513-519.CrossRefPubMed
5.
go back to reference Boonla C, Krieglstein K, Bovornpadungkitti S, Strutz F, Spittau B, Predanon C, Tosukhowong P: Fibrosis and evidence for epithelial-mesenchymal transition in the kidneys of patients with staghorn calculi. BJU Int. 2011, 108 (8): 1336-1345. 10.1111/j.1464-410X.2010.10074.x.CrossRefPubMed Boonla C, Krieglstein K, Bovornpadungkitti S, Strutz F, Spittau B, Predanon C, Tosukhowong P: Fibrosis and evidence for epithelial-mesenchymal transition in the kidneys of patients with staghorn calculi. BJU Int. 2011, 108 (8): 1336-1345. 10.1111/j.1464-410X.2010.10074.x.CrossRefPubMed
6.
go back to reference Teichman JM, Long RD, Hulbert JC: Long-term renal fate and prognosis after staghorn calculus management. J Urol. 1995, 153 (5): 1403-1407. 10.1016/S0022-5347(01)67413-5.CrossRefPubMed Teichman JM, Long RD, Hulbert JC: Long-term renal fate and prognosis after staghorn calculus management. J Urol. 1995, 153 (5): 1403-1407. 10.1016/S0022-5347(01)67413-5.CrossRefPubMed
7.
go back to reference Preminger GM, Assimos DG, Lingeman JE, Nakada SY, Pearle MS, Wolf JS, Panel AUANG: Chapter 1: AUA guideline on management of staghorn calculi: diagnosis and treatment recommendations. J Urol. 2005, 173 (6): 1991-2000. 10.1097/01.ju.0000161171.67806.2a.CrossRefPubMed Preminger GM, Assimos DG, Lingeman JE, Nakada SY, Pearle MS, Wolf JS, Panel AUANG: Chapter 1: AUA guideline on management of staghorn calculi: diagnosis and treatment recommendations. J Urol. 2005, 173 (6): 1991-2000. 10.1097/01.ju.0000161171.67806.2a.CrossRefPubMed
8.
go back to reference Viprakasit DP, Sawyer MD, Herrell SD, Miller NL: Changing composition of staghorn calculi. J Urol. 2011, 186 (6): 2285-2290. 10.1016/j.juro.2011.07.089.CrossRefPubMed Viprakasit DP, Sawyer MD, Herrell SD, Miller NL: Changing composition of staghorn calculi. J Urol. 2011, 186 (6): 2285-2290. 10.1016/j.juro.2011.07.089.CrossRefPubMed
9.
go back to reference Mandel N, Mandel I, Fryjoff K, Rejniak T, Mandel G: Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J Urol. 2003, 169 (6): 2026-2029. 10.1097/01.ju.0000065592.55499.4e.CrossRefPubMed Mandel N, Mandel I, Fryjoff K, Rejniak T, Mandel G: Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J Urol. 2003, 169 (6): 2026-2029. 10.1097/01.ju.0000065592.55499.4e.CrossRefPubMed
10.
go back to reference Parks JH, Worcester EM, Coe FL, Evan AP, Lingeman JE: Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int. 2004, 66 (2): 777-785. 10.1111/j.1523-1755.2004.00803.x.CrossRefPubMed Parks JH, Worcester EM, Coe FL, Evan AP, Lingeman JE: Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int. 2004, 66 (2): 777-785. 10.1111/j.1523-1755.2004.00803.x.CrossRefPubMed
11.
go back to reference Schwab SJ, Bander SJ, Klahr S: Renal infection in autosomal dominant polycystic kidney disease. Ame J Med. 1987, 82 (4): 714-718. 10.1016/0002-9343(87)90005-2.CrossRef Schwab SJ, Bander SJ, Klahr S: Renal infection in autosomal dominant polycystic kidney disease. Ame J Med. 1987, 82 (4): 714-718. 10.1016/0002-9343(87)90005-2.CrossRef
12.
go back to reference Hwang JH, Park HC, Jeong JC, Ha Baek S, Han MY, Bang K, Cho JY, Yu SH, Yang J, Oh KH, et al: Chronic asymptomatic pyuria precedes overt urinary tract infection and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrol. 2013, 14: 1-10.1186/1471-2369-14-1.CrossRefPubMedPubMedCentral Hwang JH, Park HC, Jeong JC, Ha Baek S, Han MY, Bang K, Cho JY, Yu SH, Yang J, Oh KH, et al: Chronic asymptomatic pyuria precedes overt urinary tract infection and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrol. 2013, 14: 1-10.1186/1471-2369-14-1.CrossRefPubMedPubMedCentral
13.
go back to reference Mishra S, Sabnis RB, Desai MR: Percutaneous nephrolithotomy monotherapy for staghorn: paradigm shift for ‘staghorn morphometry’ based clinical classification. Curr opin urology. 2012, 22 (2): 148-153. 10.1097/MOU.0b013e32834fc306.CrossRef Mishra S, Sabnis RB, Desai MR: Percutaneous nephrolithotomy monotherapy for staghorn: paradigm shift for ‘staghorn morphometry’ based clinical classification. Curr opin urology. 2012, 22 (2): 148-153. 10.1097/MOU.0b013e32834fc306.CrossRef
14.
go back to reference Umbreit EC, Childs MA, Patterson DE, Torres VE, LeRoy AJ, Gettman MT: Percutaneous nephrolithotomy for large or multiple upper tract calculi and autosomal dominant polycystic kidney disease. J Urol. 2010, 183 (1): 183-187. 10.1016/j.juro.2009.08.141.CrossRefPubMedPubMedCentral Umbreit EC, Childs MA, Patterson DE, Torres VE, LeRoy AJ, Gettman MT: Percutaneous nephrolithotomy for large or multiple upper tract calculi and autosomal dominant polycystic kidney disease. J Urol. 2010, 183 (1): 183-187. 10.1016/j.juro.2009.08.141.CrossRefPubMedPubMedCentral
15.
go back to reference Ng CS, Yost A, Streem SB: Nephrolithiasis associated with autosomal dominant polycystic kidney disease: contemporary urological management. J Urol. 2000, 163 (3): 726-729. 10.1016/S0022-5347(05)67792-0.CrossRefPubMed Ng CS, Yost A, Streem SB: Nephrolithiasis associated with autosomal dominant polycystic kidney disease: contemporary urological management. J Urol. 2000, 163 (3): 726-729. 10.1016/S0022-5347(05)67792-0.CrossRefPubMed
16.
go back to reference Al-Kandari AM, Shoma AM, Eraky I, El-Kenawy MR, Al-Eezi H, El-Kappany HA: Percutaneous nephrolithotomy for management of upper urinary tract calculi in patients with autosomal dominant polycystic kidney disease. Urol. 2009, 74 (2): 273-277. 10.1016/j.urology.2008.07.036.CrossRefPubMed Al-Kandari AM, Shoma AM, Eraky I, El-Kenawy MR, Al-Eezi H, El-Kappany HA: Percutaneous nephrolithotomy for management of upper urinary tract calculi in patients with autosomal dominant polycystic kidney disease. Urol. 2009, 74 (2): 273-277. 10.1016/j.urology.2008.07.036.CrossRefPubMed
Metadata
Title
Complete staghorn calculus in polycystic kidney disease: infection is still the cause
Authors
Zhiguo Mao
Jing Xu
Chaoyang Ye
Dongping Chen
Changlin Mei
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-168

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.